A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Summary

The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.

Timeline

Start

2004-11

Primary completion

2005-10

Completion

2005-11

Drugs

Indications